| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
MARI Stock Overview
Marinomed Biotech AG, a biopharmaceutical company, develops therapies for patients suffering from serious viral infectious diseases and autoreactive immune disorders in Austria, other European countries, and internationally.
Marinomed Biotech Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €64.40 |
| 52 Week High | €119.50 |
| 52 Week Low | €58.60 |
| Beta | 0.091 |
| 1 Month Change | 0.94% |
| 3 Month Change | -6.67% |
| 1 Year Change | -42.24% |
| 3 Year Change | -34.95% |
| 5 Year Change | n/a |
| Change since IPO | -15.26% |
Recent News & Updates
Shareholder Returns
| MARI | AT Pharmaceuticals | AT Market | |
|---|---|---|---|
| 7D | -0.6% | -2.3% | 1.6% |
| 1Y | -42.2% | -1.3% | -6.7% |
Return vs Industry: MARI underperformed the Austrian Pharmaceuticals industry which returned -1.3% over the past year.
Return vs Market: MARI underperformed the Austrian Market which returned -6.7% over the past year.
Price Volatility
| MARI volatility | |
|---|---|
| MARI Average Weekly Movement | 5.1% |
| Pharmaceuticals Industry Average Movement | 5.8% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in AT Market | 7.2% |
| 10% least volatile stocks in AT Market | 2.8% |
Stable Share Price: MARI is not significantly more volatile than the rest of Austrian stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: MARI's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 42 | Andreas Grassauer | https://www.marinomed.com |
Marinomed Biotech AG, a biopharmaceutical company, develops therapies for patients suffering from serious viral infectious diseases and autoreactive immune disorders in Austria, other European countries, and internationally. It operates through two segments, Carragelose and Marinosolv. The company develops Marinosolv, a technology platform that increases the bioavailability of hardly soluble compounds for the treatment of sensitive tissues, such as eyes and nose; and.
Marinomed Biotech Fundamentals Summary
| MARI fundamental statistics | |
|---|---|
| Market Cap | €97.00m |
| Earnings (TTM) | -€5.63m |
| Revenue (TTM) | €11.82m |
8.2x
P/S Ratio-17.2x
P/E RatioIs MARI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MARI income statement (TTM) | |
|---|---|
| Revenue | €11.82m |
| Cost of Revenue | €9.77m |
| Gross Profit | €2.05m |
| Other Expenses | €7.68m |
| Earnings | -€5.63m |
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
Aug 25, 2022
| Earnings per share (EPS) | -3.74 |
| Gross Margin | 17.32% |
| Net Profit Margin | -47.65% |
| Debt/Equity Ratio | -3,684.5% |
How did MARI perform over the long term?
See historical performance and comparisonValuation
Is MARI undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Analyst Forecast
Key Valuation Metric
Which metric is best to use when looking at relative valuation for MARI?
Other financial metrics that can be useful for relative valuation.
| What is MARI's n/a Ratio? | |
|---|---|
| n/a Ratio | 0x |
| n/a | n/a |
| Market Cap | €97.00m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 9.1x |
| Enterprise Value/EBITDA | -24.2x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does MARI's PS Ratio compare to its peers?
| MARI PS Ratio vs Peers |
|---|
| Company | PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 2.7x | ||
530199 Themis Medicare | 2x | n/a | ₹7.4b |
506879 Gujarat Themis Biosyn | 5.7x | n/a | ₹7.3b |
STHZ StateHouse Holdings | 1.5x | 58.4% | CA$126.2m |
APPH Apontis Pharma | 1.8x | 16.4% | €92.7m |
MARI Marinomed Biotech | 8.2x | 24.9% | €97.0m |
Price-To-Sales vs Peers: MARI is expensive based on its Price-To-Sales Ratio (8.2x) compared to the peer average (2.7x).
Price to Earnings Ratio vs Industry
How does MARI's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?
Price-To-Sales vs Industry: MARI is expensive based on its Price-To-Sales Ratio (8.2x) compared to the European Pharmaceuticals industry average (4.1x)
Price to Sales Ratio vs Fair Ratio
What is MARI's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 8.2x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate MARI's Price-To-Sales Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of MARI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: MARI (€64.4) is trading below our estimate of fair value (€260.84)
Significantly Below Fair Value: MARI is trading below fair value by more than 20%.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Future Growth
How is Marinomed Biotech forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Future Growth Score
2/6Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
8.2%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MARI is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: MARI is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: MARI is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: MARI's revenue (24.9% per year) is forecast to grow faster than the Austrian market (-1.1% per year).
High Growth Revenue: MARI's revenue (24.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if MARI's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Past Performance
How has Marinomed Biotech performed over the past 5 years?
Past Performance Score
0/6Past Performance Score 0/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
8.5%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MARI is currently unprofitable.
Growing Profit Margin: MARI is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: MARI is unprofitable, but has reduced losses over the past 5 years at a rate of 8.5% per year.
Accelerating Growth: Unable to compare MARI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MARI is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (18.2%).
Return on Equity
High ROE: MARI's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
Discover strong past performing companies
Financial Health
How is Marinomed Biotech's financial position?
Financial Health Score
1/6Financial Health Score 1/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: MARI has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: MARI has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: MARI has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: MARI's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MARI has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if MARI has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Discover healthy companies
Dividend
What is Marinomed Biotech current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MARI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MARI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MARI's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MARI's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as MARI has not reported any payouts.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
4.0yrs
Average management tenure
CEO
Andreas Grassauer (53 yo)
16.58yrs
Tenure
€324,000
Compensation
Mr. Andreas Grassauer, PhD, is a Co-Founder of Marinomed Biotechnology GmbH in 2006 and serves as its Chairman of Management Board and has been Chief Executive Officer since 2006. Mr. Grassauer has co-foun...
CEO Compensation Analysis
Compensation vs Market: Insufficient data to establish whether Andreas's total compensation is reasonable compared to companies of similar size in the Austrian market.
Compensation vs Earnings: Andreas's compensation has been consistent with company performance over the past year.
Leadership Team
Experienced Management: MARI's management team is considered experienced (4 years average tenure).
Board Members
Experienced Board: MARI's board of directors are considered experienced (4.5 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2%.
Top Shareholders
Company Information
Marinomed Biotech AG's employee growth, exchange listings and data sources
Key Information
- Name: Marinomed Biotech AG
- Ticker: MARI
- Exchange: WBAG
- Founded: 2006
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: €96.997m
- Shares outstanding: 1.51m
- Website: https://www.marinomed.com
Number of Employees
Location
- Marinomed Biotech AG
- Hovengasse 25
- Korneuburg
- Lower Austria
- 2100
- Austria
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/08/13 00:00 |
| End of Day Share Price | 2022/08/12 00:00 |
| Earnings | 2022/03/31 |
| Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.